- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07635108
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) (PINPOINT)
Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PINPOINT is a prospective, investigator-initiated, single-centre, single-arm phase 2 trial of single-fraction MR-guided SBRT in patients with nodal oligorecurrent prostate cancer. Eligible men have PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen following curatively intended local treatment.
All patients are simulated with MRI in treatment position and treated with 24 Gy in 1 fraction to the gross tumour volume (GTV) using inverse-planned step-and-shoot IMRT on an MR-linac. No CTV margin is added (CTV = GTV); PTV margins account for motion and set-up uncertainty. Normal-tissue constraints are prioritised over target coverage.
The primary endpoint is cumulative CTCAE v5 grade ≥4 treatment-related toxicity within 6 months. Sample size follows a Simon two-stage design (H0: grade 4-5 TRAE rate 15%; H1: 4%; one-sided α = 5%, power 80%), with an interim analysis after 6-month follow-up of the first 16 patients and a total of 48 patients. Follow-up continues for 5 years. Toxicity (CTCAE v5), quality of life (EQ-5D-5L, EORTC QLQ-C30) and patient-reported outcomes (PRO-CTCAE) are collected at baseline and through follow-up; PSA and PSMA-PET/CT (on rising PSA) follow standard of care.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Kristine S Nielsen, MD
- Telefonnummer: +45 31269894
- E-post: kristine.skovly.nielsen@rsyd.dk
Studer Kontakt Backup
- Navn: Tine Schytte, Professor
- Telefonnummer: +45 21421114
- E-post: tine-schytte@rsyd.dk
Studiesteder
-
-
-
Odense, Danmark
- Department of Oncology, Odense University Hospital
-
Ta kontakt med:
- Kristine S Nielsen, MD
- Telefonnummer: +45 31269894
- E-post: kristine.skovly.nielsen@rsyd.dk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Signed informed consent
- Histologically proven initial diagnosis of adenocarcinoma of the prostate
- ECOG performance status 0-2
- Biochemical recurrence after curatively intended local treatment (radical prostatectomy and/or radiotherapy), with PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen
- Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment
- Life expectancy > 6 months
- Lymph node size ≤ 2 cm
Exclusion Criteria:
- Medical contraindications to MRI
- Inability to tolerate the physical set-up required for SABR
- Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury
- Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)
- Uncontrolled intercurrent illness
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single-fraction MR-guided SBRT
All participants receive 24 Gy in a single fraction to the GTV, delivered with MR-guided SBRT.
|
Participants will receive 24 Gy in 1 fraction to a lymph node.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with cumulative CTCAE v5.0 grade ≥4 treatment-related adverse events
Tidsramme: Within 6 months after completion of radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after completion of radiotherapy
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with late adverse events (CTCAE v5.0)
Tidsramme: 1, 1,5, 2, 3 and 5 years
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effect. Possible scores range from 0-5, with higher scores indicating a worse outcome. |
1, 1,5, 2, 3 and 5 years
|
|
Percentage of participants free from local progression (PSMA-PET/CT-verified), estimated by time-to-event analysis
Tidsramme: From radiotherapy until local progression or last follow-up, up to 5 years
|
Defined as freedom from PSMA-verified relapse within the treated area.
In the case of significant increase in PSA, a PSMA will be performed as to local guidelines.
Local control will be evaluated at a lesion level, lesion by lesion.
Within the treated area is defined as within or adjacent to the planning target volume (PTV).
|
From radiotherapy until local progression or last follow-up, up to 5 years
|
|
Median clinical progression-free survival
Tidsramme: From radiotherapy up to 5 years
|
Defined as time from inclusion to any new node or distant metastases recurrence.
|
From radiotherapy up to 5 years
|
|
Median time to initiation of palliative ADT (ADT-free survival)
Tidsramme: From inclusion up to 5 years
|
ADT-free survival is defined as the time from trial randomization to start of hormonal treatment
|
From inclusion up to 5 years
|
|
Number of participants with acute adverse events (CTCAE v5.0), by maximum grade
Tidsramme: Within 6 months after radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after radiotherapy
|
|
Median overall survival
Tidsramme: From inclusion up to 5 years
|
Overall survival is defined as time form inclusion to death from any cause
|
From inclusion up to 5 years
|
|
Mean change from baseline in EQ-5D-5L index (utility) score
Tidsramme: Baseline, 2 weeks, 3,6 and 12 months
|
The EQ-5D-5L is a standardized, validated generic instrument for health-related quality of life.
It comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels.
Responses are converted to a single summary index (utility) score using a country-specific (Danish) value set, anchored at 1 = full health and 0 = death, with negative values possible for health states considered worse than death; higher scores indicate better health-related quality of life.
The outcome is reported as the mean change from baseline in the EQ-5D-5L index score at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
|
Mean change from baseline in EORTC QLQ-C30 Global Health Status / QoL scale score
Tidsramme: Baseline, 2 weeks, 3, 6 and 12 months
|
The EORTC QLQ-C30 (version 3.0) is a validated cancer-specific questionnaire for assessing health-related quality of life in clinical trials.
It contains 30 items comprising a global health status / quality of life scale, five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), and several single-item symptom and financial-impact measures.
Raw scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual; for the global health status / QoL scale a higher score indicates better quality of life.
This outcome is reported as the mean change from baseline in the global health status / QoL scale score at each assessment time point.
|
Baseline, 2 weeks, 3, 6 and 12 months
|
|
Number of participants reporting symptomatic adverse events as assessed by PRO-CTCAE
Tidsramme: Baseline, 2 weeks, 3,6 and 12 months
|
PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) is a validated patient-reported measurement system developed by the NCI to capture symptomatic toxicity in cancer clinical trials.
A predefined subset of PRO-CTCAE items is used in this trial.
Each symptom is rated by the patient over the prior 7 days across the applicable attributes - frequency (never to almost constantly), severity (none to very severe), and/or interference with usual or daily activities (not at all to very much) - each on a 5-point ordinal scale (scored 0-4).
The outcome is reported as the number of participants in each response category per item and attribute at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Patologiske prosesser
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Neoplastiske prosesser
- Neoplasma Metastase
- Patologiske tilstander, tegn og symptomer
- Prostatiske neoplasmer
- Lymfemetastase
Andre studie-ID-numre
- OP-2499
- S-20250058 (Annen identifikator: Ethics committee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .